Lactic acidosis and fatal myocardial failure due to clozapine.
OBJECTIVE
To describe a patient with neutropenic fever complicated by hyperglycemia, lactic acidosis, and fatal myocardial failure associated with clozapine therapy.


METHODS
A 37-year-old Ashkenazic Jewish man was admitted for agranulocytosis and fever, which developed after 11 weeks of clozapine monotherapy for drug-resistant schizophrenia. Complete blood counts and a routine serum chemical analysis had been normal before the treatment was initiated, and remained within normal limits during the first 10 weeks of the treatment. On the day of admission, the patient deteriorated rapidly and developed extreme hyperglycemia, severe lactic acidosis, recurrent cardiac arrest, cardiogenic shock, and coma. He died 36 hours later despite intensive treatment.


CONCLUSIONS
Clozapine intake reduced fatal aganulocytosis, associated with hyperglycemia, lactic acidosis, and heart failure. White blood cell count monitoring was insufficient to predict these adverse effects.


CONCLUSIONS
Clozapine should be avoided in high-risk patients (e.g., the elderly, women, Ashkenazic Jews).
Koren
W
W
Department of Medicine C, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Kreis
Y
Y
Duchowiczny
K
K
Prince
T
T
Sancovici
S
S
Sidi
Y
Y
Gur
H
H
D000140:Acidosis, Lactic / Q000139:chemically induced*; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000150:complications; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D017809:Fatal Outcome; D006323:Heart Arrest / Q000139:chemically induced*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007585:Jews; D007958:Leukocyte Count; D008297:Male; D012307:Risk Factors
D014150:Antipsychotic Agents; D003024:Clozapine